STAT

The art of the deal? Why a money-back guarantee for drugs is a bad idea

'Value-based pricing' for drugs sounds appealing, but it's unlikely to lower patient costs and may let pharma evade a tougher crackdown on prices.

President Trump likes to boast that he mastered the “art of the deal.”

But one option his administration is considering to encourage lower drug prices, which surfaced in a recent draft executive order, may not be much of a deal for consumers.

The concept has a clunky name — value-based pricing — but it’s fairly simple. One increasingly popular version works like this: A drug maker refunds some money to an insurer if its medicine fails to improve patient health or prevent a costly incident, such as a heart attack.

You're reading a preview, sign up to read more.

More from STAT

STAT2 min readSociety
Trump Administration Prepares To Ban Flavored E-cigarettes
The Trump administration is preparing to ban flavored e-cigarettes, Health and Human Services Secretary Alex Azar said Wednesday.
STAT4 min readSociety
An FDA Advisory Panel Is Reviewing Aimmune’s Peanut Allergy Therapy. Here’s What’s Happening
STAT's @adamfeuerstein will be watching watching a live feed of today’s FDA advisory panel to discuss a peanut allergy treatment. Follow along for updates.
STAT8 min read
‘There’s No Such Thing As Anonymity’: With Consumer DNA Tests, Sperm Banks Reconsider Long-held Promises To Donors
For generations, it was a basic tenet of donating sperm: Clinics could forever protect their clients’ identities. But, increasingly, donor anonymity is dead.